Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
The treatment demonstrated a favorable safety profile, dose-proportional pharmacokinetics, and on-target pharmacodynamic activity. Clinical benefits included durable complete metabolic remissions in ...
"As a first-in-class once-daily oral drug candidate with novel mechanism for acne treatment, ASC40 has shown positive efficacy and a good safety profile in the Phase II study ... focusing on two ...